Cargando…
New treatment possibilities for postcovid hypogonadism and erectile dysfunction.
OBJECTIVES: COVID-19 affects ACE receptors in testis, that decrease male sexual function. Recently, we have seen an increasing number of patients with erectile dysfunction (ED) appearing 3-6 months after COVID-19. The aim of our study was to determine effectiveness of hormone therapy, autologous ste...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679763/ http://dx.doi.org/10.1016/j.jsxm.2022.08.095 |
_version_ | 1784834269313499136 |
---|---|
author | Knigavko, Oleksandr V. Gramatyuk, Svetlana M. Khanzhyn, Vladyslav V. |
author_facet | Knigavko, Oleksandr V. Gramatyuk, Svetlana M. Khanzhyn, Vladyslav V. |
author_sort | Knigavko, Oleksandr V. |
collection | PubMed |
description | OBJECTIVES: COVID-19 affects ACE receptors in testis, that decrease male sexual function. Recently, we have seen an increasing number of patients with erectile dysfunction (ED) appearing 3-6 months after COVID-19. The aim of our study was to determine effectiveness of hormone therapy, autologous stem cells (ASC) and Plasma rich Platelets (PRP) - therapy in patients with hypogonadism and ED. METHODS: 123 patients with ED, which appeared 3-6 months after COVID-19. Patients were divided into 2 groups: 1(st)- 68 patients with primary hypogonadism (Tm = 7.43 + 2.1 below 12 nmol / l), and 2nd - 55 patients with secondary hypogonadism (Tm = 14.1 + 1.8 nmol / l). RESULTS: In the first group, patients were prescribed stimulating -1a group or replacement – 1b group hormone therapy for 2 months. After 2 months of hormone replacement therapy, 28 patients were diagnosed with normal T levels, but only 19 patients (61.2%) in group 1b improved their erectile function. In the second group, 55 patients were also prescribed stimulating hormone phytotherapy for 2 months and PRP therapy. 23 patients - group 2a responded to therapy with the disappearance of symptoms of hypogonadism and improvement of ED. 32 patients - group 2b - did not have significant improvements, so they received 2 courses of 5 intravenous injections of 5 million autologous stem cells (50 millions in total). 22 patients improved erectile function to normal values (IIEF -5 increased to 19.4 ± 2.2). CONCLUSIONS: 1.A significant proportion of men with postcovid hypogonadism and ED are men with normal levels of T, but reduced sensitivity of tissue receptors to T which are blocked with Interleukins (secondary hypogonadism). 2. In the treatment of secondary postcovid hypogonadism, intracavernous PRP therapy and intravenous autological stem cell therapy have a significant clinical effect and can be considered as promising treatments for this pathology. CONFLICTS OF INTEREST: All authors declare absence of any conflicts of interests. |
format | Online Article Text |
id | pubmed-9679763 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96797632022-11-22 New treatment possibilities for postcovid hypogonadism and erectile dysfunction. Knigavko, Oleksandr V. Gramatyuk, Svetlana M. Khanzhyn, Vladyslav V. J Sex Med I-10 OBJECTIVES: COVID-19 affects ACE receptors in testis, that decrease male sexual function. Recently, we have seen an increasing number of patients with erectile dysfunction (ED) appearing 3-6 months after COVID-19. The aim of our study was to determine effectiveness of hormone therapy, autologous stem cells (ASC) and Plasma rich Platelets (PRP) - therapy in patients with hypogonadism and ED. METHODS: 123 patients with ED, which appeared 3-6 months after COVID-19. Patients were divided into 2 groups: 1(st)- 68 patients with primary hypogonadism (Tm = 7.43 + 2.1 below 12 nmol / l), and 2nd - 55 patients with secondary hypogonadism (Tm = 14.1 + 1.8 nmol / l). RESULTS: In the first group, patients were prescribed stimulating -1a group or replacement – 1b group hormone therapy for 2 months. After 2 months of hormone replacement therapy, 28 patients were diagnosed with normal T levels, but only 19 patients (61.2%) in group 1b improved their erectile function. In the second group, 55 patients were also prescribed stimulating hormone phytotherapy for 2 months and PRP therapy. 23 patients - group 2a responded to therapy with the disappearance of symptoms of hypogonadism and improvement of ED. 32 patients - group 2b - did not have significant improvements, so they received 2 courses of 5 intravenous injections of 5 million autologous stem cells (50 millions in total). 22 patients improved erectile function to normal values (IIEF -5 increased to 19.4 ± 2.2). CONCLUSIONS: 1.A significant proportion of men with postcovid hypogonadism and ED are men with normal levels of T, but reduced sensitivity of tissue receptors to T which are blocked with Interleukins (secondary hypogonadism). 2. In the treatment of secondary postcovid hypogonadism, intracavernous PRP therapy and intravenous autological stem cell therapy have a significant clinical effect and can be considered as promising treatments for this pathology. CONFLICTS OF INTEREST: All authors declare absence of any conflicts of interests. Published by Elsevier Inc. 2022-11 2022-11-22 /pmc/articles/PMC9679763/ http://dx.doi.org/10.1016/j.jsxm.2022.08.095 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | I-10 Knigavko, Oleksandr V. Gramatyuk, Svetlana M. Khanzhyn, Vladyslav V. New treatment possibilities for postcovid hypogonadism and erectile dysfunction. |
title | New treatment possibilities for postcovid hypogonadism and erectile dysfunction. |
title_full | New treatment possibilities for postcovid hypogonadism and erectile dysfunction. |
title_fullStr | New treatment possibilities for postcovid hypogonadism and erectile dysfunction. |
title_full_unstemmed | New treatment possibilities for postcovid hypogonadism and erectile dysfunction. |
title_short | New treatment possibilities for postcovid hypogonadism and erectile dysfunction. |
title_sort | new treatment possibilities for postcovid hypogonadism and erectile dysfunction. |
topic | I-10 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679763/ http://dx.doi.org/10.1016/j.jsxm.2022.08.095 |
work_keys_str_mv | AT knigavkooleksandrv newtreatmentpossibilitiesforpostcovidhypogonadismanderectiledysfunction AT gramatyuksvetlanam newtreatmentpossibilitiesforpostcovidhypogonadismanderectiledysfunction AT khanzhynvladyslavv newtreatmentpossibilitiesforpostcovidhypogonadismanderectiledysfunction |